Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:33:25.523Z.
Calculation as of: 2026-10-06T15:33:25.523Z.
Quote observation: 2026-10-06T15:30:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c49465b29cefd47847e7fc901c6d20b09f101de13d3ea96f762810498d8f388
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$50.81M
EV/EBIT Ratio
N/A
TTM Avg
36.45x
3Y Avg
39.02x
5Y Avg
39.02x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| INmune Bio, Inc. (INMB) | $51.18M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.03M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.39M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.45M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $50.81M | N/A | 36.45x | 39.02x | 39.02x |
| biote Corp. (BTMD)vs › | $51.83M | 11.47x | 6.17x | 6.96x | 6.04x |
| Clene Inc. (CLNN)vs › | $50.47M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.26M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.91M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
